We focus on KL-50, a next-generation imidazotetrazine designed to induce MGMT-dependent, MMR-independent DNA crosslinks, representing a rational approach to selectively target MGMT-silenced, treatment-refractory gliomas. Here, MGMT is linked to central nervous system cancer.